Get the Stockscreener App
0.3198
9.04%
0.0265
After Hours:
.33
0.0102
+3.19%
Collplant Biotechnologies Ltd stock is traded at $0.3198, with a volume of 364.85K.
It is up +9.04% in the last 24 hours and down -45.33% over the past month.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
See More
Previous Close:
$0.2933
Open:
$0.29
24h Volume:
364.85K
Relative Volume:
4.13
Market Cap:
$4.61M
Revenue:
$2.37M
Net Income/Loss:
$-11.49M
P/E Ratio:
-0.3425
EPS:
-0.9338
Net Cash Flow:
$-10.02M
1W Performance:
-5.66%
1M Performance:
-45.33%
6M Performance:
-86.67%
1Y Performance:
-86.97%
1-Day Range:
$0.2711
$0.365
1-Week Range:
$0.2711
$0.416
52-Week Range:
$0.2711
$4.98
Collplant Biotechnologies Ltd Stock (CLGN) Company Profile
Name
Collplant Biotechnologies Ltd
Sector
Industry
Phone
-
Address
-
Compare CLGN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLGN
Collplant Biotechnologies Ltd
|
0.3198 | 4.23M | 2.37M | -11.49M | -10.02M | -0.9338 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Collplant Biotechnologies Ltd Stock (CLGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-23 | Initiated | Alliance Global Partners | Buy |
Collplant Biotechnologies Ltd Stock (CLGN) Latest News
Momentum Shift: Can CollPlant Biotechnologies Ltd sustain earnings growthGap Up & Trade Opportunity Analysis Reports - baoquankhu1.vn
CollPlant implementing cost-reduction and workforce optimization plan - TipRanks
CLGN Implements Major Cost-Cutting Measures for Future Growth - GuruFocus
CollPlant Ends AbbVie Partnership, Eyes New Opportunities Ahead - Intellectia AI
CollPlant Resets Strategy After AbbVie Ends Filler Deal, Slashes Workforce by 50% - TipRanks
CollPlant ends AbbVie deal, cuts workforce by 50% By Investing.com - Investing.com South Africa
CollPlant announces termination of development agreement with AbbVie - TipRanks
AbbVie ends CollPlant (NASDAQ: CLGN) filler pact as CollPlant slashes workforce 50% - Stock Titan
CollPlant Biotechnologies Ltd and Allergan Industrie SAS Terminate Development Agreement - marketscreener.com
Buyback Watch: Does CollPlant Biotechnologies Ltd stock have upside surprise potentialCEO Change & Capital Protection Trading Alerts - baoquankhu1.vn
CLGN SEC FilingsCollplant Biotechnologies Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Swings: What is CollPlant Biotechnologies Ltds debt to equity ratioEarnings Recap Summary & High Return Trade Guides - baoquankhu1.vn
CollPlant Files to Sell 3.3M Ordinary Shares - Intellectia AI
CollPlant Biotechnologies (NASDAQ: CLGN) registers 3.296M shares for resale - Stock Titan
Collplant Biotechnologies Ltd reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
CollPlant Biotechnologies Details 2025 Results, Bioprinting Launch and Regenerative Implant Progress - TipRanks
CollPlant Biotechnologies (NASDAQ:CLGN) Stock Surges on Q4 Revenue Beat - ChartMill
CollPlant Biotechnologies (NASDAQ: CLGN) 20-F warns on going concern and cash - Stock Titan
COLLPLANT BIOTECHNOLOGIESNEW ($CLGN) Releases Q4 2025 Earnings - Quiver Quantitative
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Nasdaq
CollPlant Biotechnologies Ltd.'s (NASDAQ:CLGN) Profit Outlook - simplywall.st
CollPlant receives Nasdaq bid price deficiency notice By Investing.com - Investing.com India
CollPlant Biotechnologies Faces Nasdaq Bid-Price Deficiency, Granted Compliance Window - TipRanks
CollPlant (CLGN) receives Nasdaq minimum bid-price notice, given time to cure - Stock Titan
CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement - PR Newswire
CollPlant receives non-compliance letter from Nasdaq - TipRanks
CollPlant Biotechnologies (CLGN) CEO Tal Yehiel details option and RSU holdings - Stock Titan
CollPlant (CLGN) director Alisa Lask details option and RSU holdings - Stock Titan
CollPlant Biotechnologies (CLGN) director reports options and RSUs on Form 3 - Stock Titan
CollPlant Biotechnologies (CLGN) director details option and RSU stake - Stock Titan
CollPlant (CLGN) VP reports 25,000 RSUs with 4-year vesting - Stock Titan
CollPlant (NASDAQ: CLGN) VP Legal details options and RSU awards - Stock Titan
CollPlant (CLGN) VP details option and restricted share unit holdings - Stock Titan
CollPlant (NASDAQ: CLGN) VP discloses options, RSUs and shares in Form 3 - Stock Titan
CollPlant (CLGN) VP details options and RSUs stake - Stock Titan
CollPlant Biotechnologies (NASDAQ: CLGN) deputy CEO details option and RSU stakes - Stock Titan
CollPlant Biotechnologies Launches Redesigned Corporate Website - Finviz
CollPlant Biotechnologies Launches Redesigned Corporate Website - Benzinga
Reviewing CG Oncology (NASDAQ:CGON) and CollPlant Biotechnologies (NASDAQ:CLGN) - Defense World
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS - Finviz
Biotech CollPlant to unveil 2025 results before U.S. market open - Stock Titan
CLGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler - Intellectia AI
CollPlant secures Korean patent for dermal filler technology - Investing.com Australia
Collplant Biotechnologies Announces Korean Patent Allowance Secured for Its Photocurable Dermal Filler - marketscreener.com
CollPlant (CLGN) Receives Korean Patent for Dermal Filler Techno - GuruFocus
CollPlant Secures Korean Patent Allowance for Photocurable Dermal Filler Platform - TipRanks
CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler - Revista ADVFN
CollPlant launches BioFlex bioink kit for 3D bioprinting By Investing.com - Investing.com India
CollPlant Launches BioFlex rhCollagen Bioink Kit to Advance 3D Bioprinting - The Globe and Mail
CollPlant to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference - Intellectia AI
Collplant Biotechnologies Ltd Stock (CLGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):